Comparison of FLT3 inhibitors with the standard treatment for FLT3-ITD mutated acute myeloid leukemia
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, which is characterized by impaired differentiation and uncontrollable proliferation of myeloid progenitor cells in the bone marrow. One-third of patients with AML have a mutation in the FMS-like tyrosine kinase 3 (FLT3) gene. The...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_US |
| Published: |
2019
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2144/32984 |